Evommune, Inc. (EVMN) Stock

Evommune, Inc. (EVMN) is a Healthcare stock trading at $21.36 (as of 2026-06-18), with a market capitalization of $836.71M and a trailing P/E of -9.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Evommune, Inc. is a clinical-stage biotechnology company developing therapies aimed at drivers of chronic inflammatory diseases. Its initial clinical programs focus on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis, including EVO756 (CSU/AD) and EVO301 (AD/UC).

Valuation — source: SEC EDGAR (first-party)
Price$21.36
Market Cap$836.71M
P/E Ratio-9.0
EV / EBITDA-8.0
Price / Book2.53
Price / Sales76.94
DCF Value (model)$-34.98
DCF Upside vs Price-263.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$13.00M
Net Margin-529.8%
Return on Equity-25.0%
Current Ratio20.36
Revenue Growth (YoY)-100.0%
EPS Growth (YoY)-93.2%
FCF Growth (YoY)15.4%
Financial Health — source: SEC EDGAR
Altman Z-Score22.03 (safe)
Valuation vs Sector & Industry
Stock P/E-9.0
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-143.0%
vs Industry-152.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderEQT Fund Management S.a r.l. ($113.33M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOLuis C. Pena
Employees45
CountryUS
IPO Date2025-11-06

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • SELLAS Life Sciences Group, Inc. (SLS)
  • Corvus Pharmaceuticals, Inc. (CRVS)
  • Alto Neuroscience, Inc. (ANRO)
  • Design Therapeutics, Inc. (DSGN)
  • Kyverna Therapeutics, Inc. (KYTX)
  • LB Pharmaceuticals Inc Common Stock (LBRX)
  • Ironwood Pharmaceuticals, Inc. (IRWD)
  • Assembly Biosciences, Inc. (ASMB)
EVMN earnings history · EVMN institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.